| Literature DB >> 33456658 |
Louardi Mounir1,2, Simou Mehdi1,2, Fahmaoui Kawtar1,2, Mansour Akram1,2, Et-Tahir Youness1,2, Tabat Meryem1,2, Joutey Tahiri Othmane1,2, Elkhaouri Imane1,2, Ezzouine Hanane1,2, Charra Boubakar1,2, Camara Marieme2,3, Lamchahab Mouna2,3, Harrach Asmaa2,3, Quessar Asmaa2,3.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe, leading to the declaration of a pandemic. While most present mild symptoms, it appears as though nearly 20% of confirmed patients develop significant complications. At this time of uncertainty, we are struggling to provide appropriate care to hematological cancer patients. We need to weigh the risks and benefits of giving cancer treatment against the odds of infecting them with COVID-19. As hematological cancer patients are immunocompromised and there are high chances of exposure during hospital visits, they can get infected and outcome can be fatal. So in this case report, we intend to discuss the possible impact of the current COVID-19 pandemic on patients with acute leukaemia in terms of diagnosis, chemotherapy, and prophylactic measures. Copyright: Louardi Mounir et al.Entities:
Keywords: COVID-19; Leukaemia; chemotherapy
Year: 2020 PMID: 33456658 PMCID: PMC7796834 DOI: 10.11604/pamj.supp.2020.37.34.25501
Source DB: PubMed Journal: Pan Afr Med J